HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stada’s Natures Aid Launches Children’s Supplement Range In UK

Executive Summary

Stada Arzneimittel's UK Natures Aid subsidiary adds a new, fun line of children's VMS products to its portfolio. 

You may also be interested in...

German Marketing Round-Up: Stada VMS Additions, Bayer On-The-Go Aspirin, Pädia Cough Switch

The latest marketing news from Germany's OTC market: Stada extends Eunova VMS line with two launches; Bayer adds on-the-go pain relief option with Aspirin Complex; and Pädia launches levodropropizine-based cough suppressants under its Quimbo brand.

Stada's Sales Grow Double Digits In 2021

Stada strengthened its position as Europe's fourth-largest OTC player in 2021 as sales at its Consumer Healthcare business jumped by 15%.

Stada Wins Battle To Keep Hoggar Night Sleep Aid OTC In Germany

Stada has won a two year battle to keep its Hoggar Night sleep aid (doxylamine) available OTC for German adults aged 65 and older.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts